 |
|
|
| |
PHARMACOKINETIC INTERACTION BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND RITONAVIR-BOOSTED HIV-1 PROTEASE INHIBITORS ATAZANAVIR, LOPINAVIR, AND DARUNAVIR
|
| |
| |
Reported by Jules Levin
Presented at the 19th Conference on Retroviruses and Opportunistic Infections,
March 5-8, 2012, Seattle, Washington, USA.
EGJ Hulskotte ,1 H-P Feng,2 F Xuan ,2 MGJA van Zutven,1* E O'Mara,2 S Youngberg,3 JA Wagner,2 JR Butterton 2
1Merck Sharp & Dohme Corp., The Netherlands; 2Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 3Celerion, Lincoln, NE, USA
|
| |
|
|
|
|
|
